Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 84

Sort by

Sort Order Select

Journal Articles

High Expression of the Resistant Factor YY1 and Low Expression of the RKIP Chemosensitizing Factor in Multiple Myeloma: Delineation of Several Crosstalk Pathways That Regulate the Expression of These Factors

Stephanie Wottrich, Bachelor of Science, Samantha Kaufhold, Bachelor of Science, Stavroula Baritaki, PhD, Benjamin Bonavida, PhD

Blood (2017) 130 (Supplement 1): 5417.

https://doi.org/10.1182/blood.V130.Suppl_1.5417.5417

Published: 2017

Journal Articles

Regulation of Drug Resistance Via the Overexpression of Phopho-RKIP (P-RKIP) in Multiple Myeloma: Dephosphorylation of P-RKIP Reverses Drug Resistance

Devasis Chatterjee, Ph. D, Stavroula Baritaki, PhD, Benjamin Bonavida, PhD

Blood (2017) 130 (Supplement 1): 4971.

https://doi.org/10.1182/blood.V130.Suppl_1.4971.4971

Published: 2017

Journal Articles

Overexpression of Raf Kinase Inhibitor Protein (RKIP) in Multiple Myeloma and Its Molecular Signature

Anna Shvartsur, Hermes Garban, MD PhD, Benjamin Bonavida, PhD

Blood (2016) 128 (22): 5673.

https://doi.org/10.1182/blood.V128.22.5673.5673

Published: 2016

Journal Articles

Yin Yang 1 (YY1) Acting Primarily As an Oncogene and Rarely As a Tumor Suppressor in Distinct Hematological Malignancies: Prognostic and Therapeutic Implications

Samantha Kaufhold, Stephanie Wottrich, Hermes Garban, MD PhD, Massimo Libra, MD Ph.D., Benjamin Bonavida, PhD

Blood (2016) 128 (22): 5122.

https://doi.org/10.1182/blood.V128.22.5122.5122

Published: 2016

Journal Articles

A Bioinformatics Approach Revealed a Differential Expression of RKIP-Related Genes in Pre-Multiple Myeloma and Multiple Myeloma: Clinical Implications

Anna Shvartsur, Devasis Chatterjee, PhD, Haiming Chen, MD PhD, James Berenson, MD, Hermes Garban, MD PhD, Benjamin Bonavida, PhD

Blood (2015) 126 (23): 5309.

https://doi.org/10.1182/blood.V126.23.5309.5309

Published: 2015

Journal Articles

In silico Tissue-Based Expression Analysis of YY1 and Cancer Stem Cell (CSC) Transcription Factors in Hematological Malignancies: Unraveling New Therapeutic Targets

Samantha Kaufhold, Hermes Garban, MD PhD, Benjamin Bonavida, PhD

Blood (2015) 126 (23): 4814.

https://doi.org/10.1182/blood.V126.23.4814.4814

Published: 2015

Journal Articles

KLF4 and YY1 Are Resistant Factors in NHL and Potential Therapeutic Targets: The New Resistant NF-κb/YY1/KLF4/Bcl xL /Mcl-1 Axis

Mayra R Montecillo-Aguado, MsC, Gabriel G Vega, PhDstudent, Hector Mayani, PhD, Sara Huerta-Yepez, PhD, Benjamin Bonavida, PhD, Otoniel Martinez-Maza, PhD, Mario I. Vega, PhD

Blood (2015) 126 (23): 1466.

https://doi.org/10.1182/blood.V126.23.1466.1466

Published: 2015

Journal Articles

Cooperation Between the CD20 Receptor and hIFN-Alpha Receptor in Overriding the Blocked CD20 Cell-Signaling in Rituximab-Resistant B-NHL By the Fusion Protein Anti-CD20-hIFN-Alpha

Gabriel G Vega, PhDstudent, Luz A Franco-Cea, Sara Huerta-Yepez, PhD, Hector Mayani, PhD, Otoniel Martinez-Maza, PhD, Benjamin Bonavida, PhD, Mario I. Vega, PhD

Blood (2015) 126 (23): 1468.

https://doi.org/10.1182/blood.V126.23.1468.1468

Published: 2015

Journal Articles

Increased M2 Macrophages in Multiple Myeloma Patients with Progressive Disease and Down-Regulated Polarization with the JAK2 Inhibitor Ruxolitinib

Haiming Chen, MD, PhD, Eric Sanchez, BA, Mingjie Li, BS, Cathy Wang, BS, Abby Gillespie, BS, Anna Shvartsur, Suzie Vardanyan, MS, Nika M Harutyunyan, Gigi Garzio, George Tang, PhD, Benjamin Bonavida, PhD, James R. Berenson, MD

Blood (2014) 124 (21): 4106.

https://doi.org/10.1182/blood.V124.21.4106.4106

Published: 2014

Journal Articles

Anti-Myeloma Activity by the Combination of the JAK2 Inhibitor Ruxolitinib with Lenalidomide and Corticosteroids

Blood (2014) 124 (21): 2114.

https://doi.org/10.1182/blood.V124.21.2114.2114

Published: 2014

Journal Articles

Circulating Bcma Binding to Its Ligand BAFF Prevents Normal Antibody Production in Multiple Myeloma Patients

Eric Sanchez, BA, Abigail Gillespie, Nika M Harutyunyan, George Tang, PhD, Jillian Gottlieb, Suzie Vardanyan, MS, Mingjie Li, BS, Claudia Andreu-Vieyra, Michael Ghermezi, Cathy Wang, BS, Joseph Ben-Zvi, Gigi Garzio, Judith Finlay, PhD, Benjamin Bonavida, PhD, Haiming Chen, MD, PhD, James R. Berenson, MD

Blood (2014) 124 (21): 4713.

https://doi.org/10.1182/blood.V124.21.4713.4713

Published: 2014

Journal Articles

Increased M2 Macrophages and Higher Levels Of The Tribble Family Member Trib1 In Monocytes Are Associated With Progressive Disease In Multiple Myeloma (MM) Patients

Haiming Chen, MD., Ph.D, Mingjie Li, Suzie Vardanyan, Jillian Gottlieb, Cathy Wang, Kevin Delijani, Joseph Ben-Zvi, Mitchell Song, Ran Halleluyan, Eric Sanchez, Benjamin Bonavida, PhD, James R. Berenson, MD

Blood (2013) 122 (21): 3127.

https://doi.org/10.1182/blood.V122.21.3127.3127

Published: 2013

Journal Articles

Rituximab Inhibits the PI3K/Akt Survival Pathway In B-NHL Cells Via Induction of the PTEN Tumor Suppressor: Pivotal Roles of the Inhibition of the PTEN Repressors Snail and YY1

Stavroula Baritaki, PhD, Eriko Suzuki, Ph.D, Mario I. Vega, PhD, Haiming Chen, MD, PhD, James R. Berenson, MD, Benjamin Bonavida, PhD

Blood (2010) 116 (21): 3152.

https://doi.org/10.1182/blood.V116.21.3152.3152

Published: 2010

Journal Articles

An ADCC-Independent Mechanism of Rituximab-Mediated B-NHL Cells Depletion Via Sensitization to Cell Death through the Expression of TRAIL on NK Cells

Mario I. Vega, PhD, Sara Huerta-Yepez, PhD, Melisa Martinez-Paniagua, BSc, MSc, Stavroula Baritaki, PhD, Benjamin Bonavida, PhD

Blood (2010) 116 (21): 4919.

https://doi.org/10.1182/blood.V116.21.4919.4919

Published: 2010

Journal Articles

Reversal of Drug/TRAIL-Resistant B-NHL Cells to Apoptosis by the Combination of Rituximab (anti-CD20) and Either Mapatumumab or Lexatumumab

Mario I. Vega, PhD, Sara Huerta-Yepez, PhD, Melisa Martinez-Paniagua, BSc, MSc, Stavroula Baritaki, PhD, Haiming Chen, MD, PhD, James R. Berenson, MD, Benjamin Bonavida, PhD

Blood (2010) 116 (21): 4931.

https://doi.org/10.1182/blood.V116.21.4931.4931

Published: 2010

Journal Articles

Photodynamic Therapy (PDT)-Mediated Inhibition of the Transcription Factor Yin Yang 1 (YY1) That Regulates Resistance In Lymphoma

Valentina Rapozzi, Ph.D, Sara Huerta-Yepez, PhD, Abhijeet Joshi, Mario I. Vega, PhD, Stavroula Baritaki, PhD, Luigi E. Xodo, Ph.D, Benjamin Bonavida, PhD

Blood (2010) 116 (21): 5113.

https://doi.org/10.1182/blood.V116.21.5113.5113

Published: 2010

Journal Articles

Multiple Myeloma (MM) Highly Expresses CGEN-928 and the Anti-CGEN-928 TM21 Antibody Markedly Inhibits the Growth of MM Cells and Enhances the Anti-Myeloma Effects of Dexamethasone, Melphalan and Bortezomib

Haiming Chen, MD, PhD, Mingjie Li, Cathy Wang, Jessica Wang, Eric Sanchez, Zhi-Wei Li, PhD, Benjamin Bonavida, PhD, Ofer Levy, Liat Dassa, Gady Cojocaru, MD, James R. Berenson, MD, Zurit Levine, PhD

Blood (2010) 116 (21): 4067.

https://doi.org/10.1182/blood.V116.21.4067.4067

Published: 2010

Journal Articles

Blockage of TRAF6 by Dominant Negative Peptides to Inhibit Multiple Myeloma (MM) Cell Proliferation and Osteoclast Formation through NF-κB, JNK and AKT Signal Transduction Pathways

Mingjie Li, Eric Sanchez, Cathy Wang, Megan Schultz, Jessica Wang, Emily Wong, Zhi-Wei Li, PhD, Haiming Chen, MD, PhD, Benjamin Bonavida, PhD, Eddie E Chou, James R. Berenson, MD

Blood (2010) 116 (21): 4068.

https://doi.org/10.1182/blood.V116.21.4068.4068

Published: 2010

Journal Articles

Lack of Binding of Monoclonal Protein Produced by Multiple Myeloma (MM) Cells to FcγRIIb Reduces Immunoreceptor Tyrosine-Based Inhibitory Motif (ITIM) Signaling and Provides the Rationale for a Novel Therapeutic Approach to MM

Jennifer Li, Mingjie Li, Cathy Wang, Jessica Wang, Eric Sanchez, Zhi-Wei Li, PhD, Benjamin Bonavida, PhD, Haiming Chen, MD, PhD, James R. Berenson, MD

Blood (2010) 116 (21): 455.

https://doi.org/10.1182/blood.V116.21.455.455

Published: 2010

Journal Articles

The Pivotal Role of Yin Yang 1 (YY1) Inhibition (and downstream Bcl-2/Bcl xl ) by Galiximab (anti-CD80 mAb) In the Reversal of Resistance of B-NHL Cells to Chemotherapy

Melisa Martinez-Paniagua, BSc, MSc, Mario I. Vega, PhD, Sara Huerta-Yepez, PhD, Hari Hariharan, PhD, Haiming Chen, MD, PhD, James R. Berenson, MD, Benjamin Bonavida, PhD

Blood (2010) 116 (21): 2887.

https://doi.org/10.1182/blood.V116.21.2887.2887

Published: 2010

NARROW

High Expression of the Resistant Factor YY1 and Low Expression of the RKIP Chemosensitizing Factor in Multiple Myeloma: Delineation of Several Crosstalk Pathways That Regulate the Expression of These Factors

Regulation of Drug Resistance Via the Overexpression of Phopho-RKIP (P-RKIP) in Multiple Myeloma: Dephosphorylation of P-RKIP Reverses Drug Resistance

Overexpression of Raf Kinase Inhibitor Protein (RKIP) in Multiple Myeloma and Its Molecular Signature

Yin Yang 1 (YY1) Acting Primarily As an Oncogene and Rarely As a Tumor Suppressor in Distinct Hematological Malignancies: Prognostic and Therapeutic Implications

A Bioinformatics Approach Revealed a Differential Expression of RKIP-Related Genes in Pre-Multiple Myeloma and Multiple Myeloma: Clinical Implications

In silico Tissue-Based Expression Analysis of YY1 and Cancer Stem Cell (CSC) Transcription Factors in Hematological Malignancies: Unraveling New Therapeutic Targets

KLF4 and YY1 Are Resistant Factors in NHL and Potential Therapeutic Targets: The New Resistant NF-κb/YY1/KLF4/Bcl xL /Mcl-1 Axis

Cooperation Between the CD20 Receptor and hIFN-Alpha Receptor in Overriding the Blocked CD20 Cell-Signaling in Rituximab-Resistant B-NHL By the Fusion Protein Anti-CD20-hIFN-Alpha

Increased M2 Macrophages in Multiple Myeloma Patients with Progressive Disease and Down-Regulated Polarization with the JAK2 Inhibitor Ruxolitinib

Anti-Myeloma Activity by the Combination of the JAK2 Inhibitor Ruxolitinib with Lenalidomide and Corticosteroids

Circulating Bcma Binding to Its Ligand BAFF Prevents Normal Antibody Production in Multiple Myeloma Patients

Increased M2 Macrophages and Higher Levels Of The Tribble Family Member Trib1 In Monocytes Are Associated With Progressive Disease In Multiple Myeloma (MM) Patients

Rituximab Inhibits the PI3K/Akt Survival Pathway In B-NHL Cells Via Induction of the PTEN Tumor Suppressor: Pivotal Roles of the Inhibition of the PTEN Repressors Snail and YY1

An ADCC-Independent Mechanism of Rituximab-Mediated B-NHL Cells Depletion Via Sensitization to Cell Death through the Expression of TRAIL on NK Cells

Reversal of Drug/TRAIL-Resistant B-NHL Cells to Apoptosis by the Combination of Rituximab (anti-CD20) and Either Mapatumumab or Lexatumumab

Photodynamic Therapy (PDT)-Mediated Inhibition of the Transcription Factor Yin Yang 1 (YY1) That Regulates Resistance In Lymphoma

Multiple Myeloma (MM) Highly Expresses CGEN-928 and the Anti-CGEN-928 TM21 Antibody Markedly Inhibits the Growth of MM Cells and Enhances the Anti-Myeloma Effects of Dexamethasone, Melphalan and Bortezomib

Blockage of TRAF6 by Dominant Negative Peptides to Inhibit Multiple Myeloma (MM) Cell Proliferation and Osteoclast Formation through NF-κB, JNK and AKT Signal Transduction Pathways

Lack of Binding of Monoclonal Protein Produced by Multiple Myeloma (MM) Cells to FcγRIIb Reduces Immunoreceptor Tyrosine-Based Inhibitory Motif (ITIM) Signaling and Provides the Rationale for a Novel Therapeutic Approach to MM

The Pivotal Role of Yin Yang 1 (YY1) Inhibition (and downstream Bcl-2/Bcl xl ) by Galiximab (anti-CD80 mAb) In the Reversal of Resistance of B-NHL Cells to Chemotherapy

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only